Snowden Capital Advisors’s iRadimed IRMD Stock Holding History

Snowden Capital Advisors’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$277K	Sell	2,899 -318	-10%	-$29K	0.01%	1108
2026 Q1	$310K	Sell	3,217 -1,045	-25%	-$105K	0.01%	1010
2025 Q4	$415K	Sell	4,262 -439	-9%	-$37.7K	0.01%	903
2025 Q3	$335K	Sell	4,701 -176	-4%	-$11.7K	0.01%	971
2025 Q2	$292K	Sell	4,877 -55	-1%	-$3.01K	0.01%	1017
2025 Q1	$259K	Buy	4,932 +761	+18%	+$42.8K	0.01%	1048
2024 Q4	$229K	Buy	+4,171	New	+$219K	0.01%	1100

Other funds holding IRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Snowden Capital Advisors's IRMD Position: Q2 2026 in Review

Snowden Capital Advisors reduced its iRadimed (IRMD) stake by 9.9% in Q2 2026, selling an estimated $29K and leaving 2,899 shares worth $277K. The position accounts for 0.01% of the portfolio, ranked #1108.

Snowden Capital Advisors first reported a position in IRMD in Q4 2024 and has held it in 7 quarters since. The position peaked at $415K in Q4 2025. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

Snowden Capital Advisors held 2,899 shares of iRadimed worth $277K as of Q2 2026.
Snowden Capital Advisors sold 318 iRadimed shares in Q2 2026, an estimated $29K.
iRadimed made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #1108 holding.
Snowden Capital Advisors first reported a position in iRadimed in Q4 2024 and has held it in 7 quarters since.
Snowden Capital Advisors's iRadimed position peaked at $415K in Q4 2025.
214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.